Shares of NeoProbe (NEOP) jump in post-trading after the FDA agrees to review its new-drug...

|By:, SA News Editor

Shares of NeoProbe (NEOP) jump in post-trading after the FDA agrees to review its new-drug application for its cancer-detection agent Lymphoseek. Shares +16% AH.